Johns Hopkins, Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland 21287
17 studies enrolling now · 99 studies all time
What they study most
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia or Myelodysplastic Syndromes, Advanced Cancer, Advanced Pancreatic Cancer, Advanced Solid Tumor, Advanced Solid Tumors, Advanced or Metastatic Solid Tumors, Advanced/Metastatic Solid Tumors or Lymphomas, Advanced/Metastatic Tumors, B-cell Malignancies, BRAF V600E
Studies at this site
- Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC — Recruiting now
- Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer — Recruiting now
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma — Recruiting now
- Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer — Recruiting now
- Digoxin Medulloblastoma Study — Recruiting now
- The COSMYC Trial (COmbined Suppression of MYC) — Recruiting now
- Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients — Recruiting now
- International Registry for Men With Advanced Prostate Cancer (IRONMAN) — Recruiting now
- Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations — Recruiting now
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response — Recruiting now
- A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation — Recruiting now
- Physician- and Patient-based Barriers to NGS Testing — Recruiting now
- Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors — Recruiting now
- Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer — Recruiting now
- A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer — Recruiting now
- Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib — Recruiting now
- PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness — Recruiting now
- Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer — Running, not enrolling
- Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations — Running, not enrolling
- A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. — Running, not enrolling
- Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion — Running, not enrolling
- Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer — Running, not enrolling
- Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation — Stopped early
- Nivolumab in Biochemically Recurrent dMMR Prostate Cancer — Completed
- An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer — Completed
- Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer — Withdrawn before enrolling
- Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) — Running, not enrolling
- Pancreatic Adenocarcinoma Signature Stratification for Treatment — Completed
- T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) — Completed
- A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma — Completed
- DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma — Completed
- A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer — Completed
- Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene — Completed
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer — Completed
- A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors — Completed
- Improving Cancer On-treatment Symptom Management — Completed
- A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) — Completed
- Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer — Running, not enrolling
- APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant — Completed
- Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer — Completed
- BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007 — Completed
- Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma — Stopped early
- A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors — Running, not enrolling
- SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation — Stopped early
- Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors — Completed
- Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials — Completed
- Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN — Completed
- A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®) — Completed
- Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients — Completed
- Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer — Completed